Fig. 6. Higher proportions of CD8⁺ senescent T cells in NSCLC advanced stages only in CMV⁺ patients.

T₈sen status was assessed by flow cytometry in 282 patients with NSCLC with tumor stage available and 31 healthy volunteers (HV; n = 21 with CMV status). (A) Proportions of CD8⁺ senescent T cells depending on NSCLC stage. (B) Proportions of CD8⁺ senescent T cells depending on NSCLC stage and CMV status. (C) LDH concentrations and number of metastatic sites according to T₈sen status. (D) LDH concentrations and number of metastatic sites according to CMV seropositivity and T₈sen status. Continuous variables were compared between populations by Mann-Whitney t test.